Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311978788> ?p ?o ?g. }
- W4311978788 endingPage "2761" @default.
- W4311978788 startingPage "2761" @default.
- W4311978788 abstract "The antineoplastic activity of the thioredoxin reductase 1 (TrxR) inhibitor, auranofin (AF), has already been investigated in various cancer mouse models as a single drug, or in combination with other molecules. However, there are inconsistencies in the literature on the solvent, dose and administration route of AF treatment in vivo. Therefore, we investigated the solvent and administration route of AF in a syngeneic SB28 glioblastoma (GBM) C57BL/6J and a 344SQ non-small cell lung cancer 129S2/SvPasCrl (129) mouse model. Compared to daily intraperitoneal injections and subcutaneous delivery of AF via osmotic minipumps, oral gavage for 14 days was the most suitable administration route for high doses of AF (10–15 mg/kg) in both mouse models, showing no measurable weight loss or signs of toxicity. A solvent comprising 50% DMSO, 40% PEG300 and 10% ethanol improved the solubility of AF for oral administration in mice. In addition, we confirmed that AF was a potent TrxR inhibitor in SB28 GBM tumors at high doses. Taken together, our results and results in the literature indicate the therapeutic value of AF in several in vivo cancer models, and provide relevant information about AF’s optimal administration route and solvent in two syngeneic cancer mouse models." @default.
- W4311978788 created "2023-01-03" @default.
- W4311978788 creator A5007235093 @default.
- W4311978788 creator A5013881555 @default.
- W4311978788 creator A5032025948 @default.
- W4311978788 creator A5039751292 @default.
- W4311978788 creator A5057833376 @default.
- W4311978788 creator A5059862918 @default.
- W4311978788 creator A5066563229 @default.
- W4311978788 creator A5069190230 @default.
- W4311978788 creator A5069580321 @default.
- W4311978788 creator A5076009877 @default.
- W4311978788 creator A5081479570 @default.
- W4311978788 creator A5091135317 @default.
- W4311978788 date "2022-12-09" @default.
- W4311978788 modified "2023-10-09" @default.
- W4311978788 title "Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model" @default.
- W4311978788 cites W1638063349 @default.
- W4311978788 cites W1890902147 @default.
- W4311978788 cites W1995443816 @default.
- W4311978788 cites W2005669070 @default.
- W4311978788 cites W2020098484 @default.
- W4311978788 cites W2020355216 @default.
- W4311978788 cites W2048994607 @default.
- W4311978788 cites W2050313963 @default.
- W4311978788 cites W2065982408 @default.
- W4311978788 cites W2080041471 @default.
- W4311978788 cites W2087377318 @default.
- W4311978788 cites W2088632292 @default.
- W4311978788 cites W2092655436 @default.
- W4311978788 cites W2109675992 @default.
- W4311978788 cites W2112932498 @default.
- W4311978788 cites W2131120911 @default.
- W4311978788 cites W2131285836 @default.
- W4311978788 cites W2138125759 @default.
- W4311978788 cites W2148406780 @default.
- W4311978788 cites W2150633938 @default.
- W4311978788 cites W2154416737 @default.
- W4311978788 cites W2186858139 @default.
- W4311978788 cites W2193658266 @default.
- W4311978788 cites W2411202502 @default.
- W4311978788 cites W2521939027 @default.
- W4311978788 cites W2522355820 @default.
- W4311978788 cites W2551212791 @default.
- W4311978788 cites W2554708139 @default.
- W4311978788 cites W2558087414 @default.
- W4311978788 cites W2783641815 @default.
- W4311978788 cites W2791406908 @default.
- W4311978788 cites W2792052811 @default.
- W4311978788 cites W2795095161 @default.
- W4311978788 cites W2810028506 @default.
- W4311978788 cites W2885358256 @default.
- W4311978788 cites W2885447570 @default.
- W4311978788 cites W2900358413 @default.
- W4311978788 cites W2901178917 @default.
- W4311978788 cites W2902166610 @default.
- W4311978788 cites W2905580912 @default.
- W4311978788 cites W2909753216 @default.
- W4311978788 cites W2912790057 @default.
- W4311978788 cites W2920419627 @default.
- W4311978788 cites W2922166085 @default.
- W4311978788 cites W2933254992 @default.
- W4311978788 cites W2935041976 @default.
- W4311978788 cites W2945855920 @default.
- W4311978788 cites W2954698710 @default.
- W4311978788 cites W2970639571 @default.
- W4311978788 cites W2989943422 @default.
- W4311978788 cites W2992670754 @default.
- W4311978788 cites W3021136295 @default.
- W4311978788 cites W3021386779 @default.
- W4311978788 cites W3045290891 @default.
- W4311978788 cites W3139219057 @default.
- W4311978788 cites W3210483070 @default.
- W4311978788 cites W3214808407 @default.
- W4311978788 cites W4211238337 @default.
- W4311978788 cites W4247898339 @default.
- W4311978788 cites W4250429122 @default.
- W4311978788 cites W617767542 @default.
- W4311978788 cites W2438417900 @default.
- W4311978788 doi "https://doi.org/10.3390/pharmaceutics14122761" @default.
- W4311978788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36559255" @default.
- W4311978788 hasPublicationYear "2022" @default.
- W4311978788 type Work @default.
- W4311978788 citedByCount "1" @default.
- W4311978788 countsByYear W43119787882023 @default.
- W4311978788 crossrefType "journal-article" @default.
- W4311978788 hasAuthorship W4311978788A5007235093 @default.
- W4311978788 hasAuthorship W4311978788A5013881555 @default.
- W4311978788 hasAuthorship W4311978788A5032025948 @default.
- W4311978788 hasAuthorship W4311978788A5039751292 @default.
- W4311978788 hasAuthorship W4311978788A5057833376 @default.
- W4311978788 hasAuthorship W4311978788A5059862918 @default.
- W4311978788 hasAuthorship W4311978788A5066563229 @default.
- W4311978788 hasAuthorship W4311978788A5069190230 @default.
- W4311978788 hasAuthorship W4311978788A5069580321 @default.
- W4311978788 hasAuthorship W4311978788A5076009877 @default.
- W4311978788 hasAuthorship W4311978788A5081479570 @default.
- W4311978788 hasAuthorship W4311978788A5091135317 @default.